Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

A new mathematical model to identify contacts with recent and remote latent tuberculosis.

Fröberg G, Wahren Borgström E, Chryssanthou E, Correia-Neves M, Källenius G, Bruchfeld J.

ERJ Open Res. 2019 Jun 10;5(2). pii: 00078-2019. doi: 10.1183/23120541.00078-2019. eCollection 2019 Apr.

2.

Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods.

Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Botterel F, Canton E, Castro C, Chen YC, Chen Y, Chryssanthou E, Dannaoui E, Garcia-Effron G, Gonzalez GM, Govender NP, Guinea J, Kidd S, Lackner M, Lass-Flörl C, Linares-Sicilia MJ, López-Soria L, Magobo R, Pelaez T, Quindós G, Rodriguez-Iglesia MA, Ruiz MA, Sánchez-Reus F, Sanguinetti M, Shields R, Szweda P, Tortorano A, Wengenack NL, Bramati S, Cavanna C, DeLuca C, Gelmi M, Grancini A, Lombardi G, Meletiadis J, Negri CE, Passera M, Peman J, Prigitano A, Sala E, Tejada M.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01651-18. doi: 10.1128/AAC.01651-18. Print 2019 Jan.

3.

Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.

Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlström O, Alomari T, Carlsson B, Pohanka A, Mansjö M, Jonsson Nordvall M, Johansson AG, Eliasson E, Werngren J, Paues J, Simonsson USH, Schön T.

J Antimicrob Chemother. 2018 Oct 1;73(10):2838-2845. doi: 10.1093/jac/dky268.

PMID:
30124844
4.

Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay.

Niward K, Ek Blom L, Davies Forsman L, Bruchfeld J, Eliasson E, Schön T, Chryssanthou E, Paues J.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00218-18. doi: 10.1128/AAC.00218-18. Print 2018 May.

5.

Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values.

Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Dannaoui E, Garcia-Effron G, Guinea J, Kidd S, Pelaez T, Sanguinetti M, Meletiadis J, Botterel F, Bustamante B, Chen YC, Chakrabarti A, Chowdhary A, Chryssanthou E, Córdoba S, Gonzalez GM, Guarro J, Johnson EM, Kus JV, Lass-Flörl C, Linares-Sicilia MJ, Martín-Mazuelos E, Negri CE, Pfaller MA, Tortorano AM.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01916-17. doi: 10.1128/AAC.01916-17. Print 2018 Apr.

6.

Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints.

Schön T, Chryssanthou E.

Int J Infect Dis. 2017 Feb;55:122-124. doi: 10.1016/j.ijid.2016.12.027. Epub 2017 Jan 6.

7.

Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.

Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, Giske CG, Kahlmeter G, Schön T.

J Antimicrob Chemother. 2016 Feb;71(2):333-8. doi: 10.1093/jac/dkv353. Epub 2015 Nov 3.

PMID:
26538509
8.

Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus.

van der Linden JW, Arendrup MC, Warris A, Lagrou K, Pelloux H, Hauser PM, Chryssanthou E, Mellado E, Kidd SE, Tortorano AM, Dannaoui E, Gaustad P, Baddley JW, Uekötter A, Lass-Flörl C, Klimko N, Moore CB, Denning DW, Pasqualotto AC, Kibbler C, Arikan-Akdagli S, Andes D, Meletiadis J, Naumiuk L, Nucci M, Melchers WJ, Verweij PE.

Emerg Infect Dis. 2015 Jun;21(6):1041-4. doi: 10.3201/eid2106.140717.

9.

Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B.

Svahn KS, Chryssanthou E, Olsen B, Bohlin L, Göransson U.

Fungal Biol Biotechnol. 2015 Jan 17;2:1. doi: 10.1186/s40694-014-0011-x. eCollection 2015.

10.

The effect of K101 Nail Solution on Trichophyton rubrum and Candida albicans growth and ultrastructure.

Hultenby K, Chryssanthou E, Klingspor L, Rensfeldt K, Strömbeck L, Faergemann J.

Mycoses. 2014 Oct;57(10):630-8. doi: 10.1111/myc.12211. Epub 2014 Jun 17.

11.

Induction of gliotoxin secretion in Aspergillus fumigatus by bacteria-associated molecules.

Svahn KS, Göransson U, Chryssanthou E, Olsen B, Sjölin J, Strömstedt AA.

PLoS One. 2014 Apr 4;9(4):e93685. doi: 10.1371/journal.pone.0093685. eCollection 2014.

12.

Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J.

Antimicrob Agents Chemother. 2013 Dec;57(12):5836-42. doi: 10.1128/AAC.01519-13. Epub 2013 Sep 9.

13.

Epidemiological analyses of tuberculosis in Archangelsk, Russia and implementation of a rapid assay for detection of resistance in this high burden setting.

Eliseev PI, Maryandyshev AO, Nikishova EI, Tarasova IV, Gorina GP, Chryssanthou E, Ridell M, Larsson LO.

Int J Mycobacteriol. 2013 Jun;2(2):103-8. doi: 10.1016/j.ijmyco.2013.04.002. Epub 2013 May 4.

14.

Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?

Schön T, Juréen P, Chryssanthou E, Giske CG, Kahlmeter G, Hoffner S, Angeby K.

J Antimicrob Chemother. 2013 Sep;68(9):2074-7. doi: 10.1093/jac/dkt150. Epub 2013 Apr 30.

PMID:
23633684
15.

Candidaemia in Sweden: a nationwide prospective observational survey.

Ericsson J, Chryssanthou E, Klingspor L, Johansson AG, Ljungman P, Svensson E, Sjölin J.

Clin Microbiol Infect. 2013 Apr;19(4):E218-21. doi: 10.1111/1469-0691.12111. Epub 2013 Jan 17.

16.

Tentative susceptibility testing breakpoint for the neuroleptic drug thioridazine, a treatment option for multi- and extensively drug resistant tuberculosis.

Ängeby K, Juréen P, Chryssanthou E, Schön T.

Int J Mycobacteriol. 2012 Dec;1(4):177-9. doi: 10.1016/j.ijmyco.2012.09.002. Epub 2012 Oct 11.

17.

Antimicrobial activity of filamentous fungi isolated from highly antibiotic-contaminated river sediment.

Svahn KS, Göransson U, El-Seedi H, Bohlin L, Larsson DG, Olsen B, Chryssanthou E.

Infect Ecol Epidemiol. 2012;2. doi: 10.3402/iee.v2i0.11591. Epub 2012 May 24.

18.

The GenoType® MTBDRplus assay for detection of drug resistance in Mycobacterium tuberculosis in Sweden.

Chryssanthou E, Angeby K.

APMIS. 2012 May;120(5):405-9. doi: 10.1111/j.1600-0463.2011.02845.x. Epub 2011 Nov 28.

PMID:
22515295
19.

Occurrence of yeasts in faecal samples from Antarctic and South American seabirds.

Chryssanthou E, Wennberg H, Bonnedahl J, Olsen B.

Mycoses. 2011 Nov;54(6):e811-5. doi: 10.1111/j.1439-0507.2011.02031.x. Epub 2011 Jun 14.

PMID:
21672044
20.

Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration.

Lignell A, Löwdin E, Cars O, Chryssanthou E, Sjölin J.

Antimicrob Agents Chemother. 2011 Jul;55(7):3099-104. doi: 10.1128/AAC.01671-10. Epub 2011 Apr 18.

21.

Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.

Schön T, Juréen P, Chryssanthou E, Giske CG, Sturegård E, Kahlmeter G, Hoffner S, Angeby KA.

Int J Tuberc Lung Dis. 2011 Apr;15(4):502-9. doi: 10.5588/ijtld.10.0238.

PMID:
21396210
22.

Epidemiology of dermatophyte infections in Stockholm, Sweden: a retrospective study from 2005-2009.

Drakensjö IT, Chryssanthou E.

Med Mycol. 2011 Jul;49(5):484-8. doi: 10.3109/13693786.2010.540045. Epub 2010 Dec 3.

PMID:
21128711
23.

Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.

Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T.

J Antimicrob Chemother. 2010 May;65(5):946-52. doi: 10.1093/jac/dkq091. Epub 2010 Mar 23.

PMID:
20332195
24.

Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.

Juréen P, Angeby K, Sturegård E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schön T.

J Clin Microbiol. 2010 May;48(5):1853-8. doi: 10.1128/JCM.00240-10. Epub 2010 Mar 17.

25.

Combs and hair-trimming tools as reservoirs for dermatophytes in juvenile tinea capitis.

Winge MC, Chryssanthou E, Wahlgren CF.

Acta Derm Venereol. 2009;89(5):536-7. doi: 10.2340/00015555-0694. No abstract available.

26.

Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.

Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Werngren J, Kahlmeter G, Hoffner SE, Angeby KA.

J Antimicrob Chemother. 2009 Oct;64(4):786-93. doi: 10.1093/jac/dkp262. Epub 2009 Jul 23.

PMID:
19633001
27.

Drug resistance and genotypic analysis of Mycobacterium tuberculosis strains from Thai tuberculosis patients.

Cheunoy W, Haile M, Chaiprasert A, Prammananan T, Cristea-Fernström M, Vondracek M, Chryssanthou E, Hoffner S, Petrini B.

APMIS. 2009 Apr;117(4):286-90.

PMID:
19343824
28.

Post-antifungal effect of amphotericin B and voriconazole against germinated Aspergillus fumigatus conidia.

Chryssanthou E, Loebig A, Sjölin J.

J Antimicrob Chemother. 2008 Jun;61(6):1309-11. doi: 10.1093/jac/dkn129. Epub 2008 Mar 26.

PMID:
18367461
29.

Extensive transmission of an isoniazid-resistant strain of Mycobacterium tuberculosis in Sweden.

Kan B, Berggren I, Ghebremichael S, Bennet R, Bruchfeld J, Chryssanthou E, Källenius G, Petersson R, Petrini B, Romanus V, Sylvan S, Kalin M.

Int J Tuberc Lung Dis. 2008 Feb;12(2):199-204.

PMID:
18230254
30.
31.
32.

Histoplasmosis in Europe: report on an epidemiological survey from the European Confederation of Medical Mycology Working Group.

Ashbee HR, Evans EG, Viviani MA, Dupont B, Chryssanthou E, Surmont I, Tomsikova A, Vachkov P, Enero B, Zala J, Tintelnot K; ECMM Working Group on; Histoplasmosis.

Med Mycol. 2008 Feb;46(1):57-65.

PMID:
17885939
33.

Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).

Cuenca-Estrella M, Arendrup MC, Chryssanthou E, Dannaoui E, Lass-Florl C, Sandven P, Velegraki A, Rodriguez-Tudela JL; AFST Subcommittee of EUCAST.

Clin Microbiol Infect. 2007 Oct;13(10):1018-22. Epub 2007 Aug 13.

34.

Diagnostics of fungal infections in the Nordic countries: we still need to improve!

Arendrup MC, Chryssanthou E, Gaustad P, Koskela M, Sandven P, Fernandez V.

Scand J Infect Dis. 2007;39(4):337-43.

PMID:
17454898
36.

Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis.

Nivenius E, van der Ploeg I, Jung K, Chryssanthou E, van Hage M, Montan PG.

Eye (Lond). 2007 Jul;21(7):968-75. Epub 2006 May 5.

PMID:
16680103
37.

Clinico-mycological profile of dermatophytosis in a reference centre for leprosy and dermatological diseases in Addis Ababa.

Woldeamanuel Y, Leekassa R, Chryssanthou E, Mengistu Y, Petrini B.

Mycopathologia. 2006 Mar;161(3):167-72.

PMID:
16482389
38.

In vitro activity of Phytolacca dodecandra (Endod) against dermatophytes.

Woldeamanuel Y, Abate G, Chryssanthou E.

Ethiop Med J. 2005 Jan;43(1):31-4.

PMID:
16370528
39.

A fatal case of severe immunodeficiency associated with disseminated Merulius tremellosus infection.

Friman V, Gisslén M, Nikkari S, Stenlid J, Chryssanthou E, Petrini B.

Scand J Infect Dis. 2006;38(1):76-8.

PMID:
16338846
40.

White variants of Trichophyton violaceum isolated in Ethiopia.

Woldeamanuel Y, Leekassa R, Petrini B, Chryssanthou E.

APMIS. 2005 Oct;113(10):708-12.

PMID:
16309431
41.

Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies.

Chryssanthou E, Cherif H, Petrini B, Kalin M, Björkholm M.

Scand J Infect Dis. 2004;36(11-12):855-9.

PMID:
15764173
42.

Prevalence of tinea capitis in Ethiopian schoolchildren.

Woldeamanuel Y, Leekassa R, Chryssanthou E, Menghistu Y, Petrini B.

Mycoses. 2005 Mar;48(2):137-41.

PMID:
15743433
43.

Dermatophytosis in Tulugudu Island, Ethiopia.

Woldeamanuel Y, Mengistu Y, Chryssanthou E, Petrini B.

Med Mycol. 2005 Feb;43(1):79-82.

PMID:
15712611
44.

Genetic diversity in clinical isolates of Mycobacterium avium complex from Guinea-Bissau, West Africa.

Koivula T, Cristea-Fernström M, Chryssanthou E, Petrini B, Källenius G.

Microbes Infect. 2004 Nov;6(14):1320-5.

PMID:
15555539
46.

No apparent association between periocular and ocular microcolonization and the degree of inflammation in patients with atopic keratoconjunctivitis.

Nivenius E, Montan PG, Chryssanthou E, Jung K, van Hage-Hamsten M, van der Ploeg I.

Clin Exp Allergy. 2004 May;34(5):725-30.

PMID:
15144463
47.

Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi.

Rodriguez-Tudela JL, Chryssanthou E, Petrikkou E, Mosquera J, Denning DW, Cuenca-Estrella M.

J Clin Microbiol. 2003 Nov;41(11):5236-7.

48.

Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery.

Studahl M, Backteman T, Stålhammar F, Chryssanthou E, Petrini B.

Acta Paediatr. 2003 Aug;92(8):980-2.

PMID:
12948078
49.

Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).

Cuenca-Estrella M, Moore CB, Barchiesi F, Bille J, Chryssanthou E, Denning DW, Donnelly JP, Dromer F, Dupont B, Rex JH, Richardson MD, Sancak B, Verweij PE, Rodríguez-Tudela JL; AFST Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.

Clin Microbiol Infect. 2003 Jun;9(6):467-74.

Supplemental Content

Loading ...
Support Center